coronavirus vaccine are now fully enrolled, and expects to release initial data on the shot’s effectiveness by the end of January.The company said roughly 45,000 participants in several countries have now signed up to receive the pharmaceutical company’s vaccine, which is being developed along with its medical research and development subsidiary, Janssen.
Johnson & Johnson’s single-dose COVID-19 vaccine candidate begins phase 3 trial “Given the high incidence of COVID-19 among the general population in the countries where the trial is being conducted, this number of participants will be sufficient to generate the data needed to determine the efficacy and safety of the Company’s investigational COVID-19 vaccine candidate,” the company said.